Adicet Announces Appointment of Dr. Bastiano Sanna to its Board of Directors
December 01 2020 - 7:00AM
Adicet Bio, Inc. (Nasdaq: ACET), a biotechnology company
discovering and developing first-in-class allogeneic gamma delta T
cell therapies for cancer and other diseases, today announced the
appointment of Bastiano Sanna, Ph.D., to its Board of Directors.
Dr. Sanna brings significant expertise in advancing research,
development and manufacturing of cell therapies. He currently
serves as Executive Vice President and Chief of Cell and Genetic
Therapies at Vertex Pharmaceuticals Incorporated.
“Dr. Sanna brings a wealth of industry experience, most notably
in the development of cell therapy, where he has established an
impressive track record with the successful development of novel
cell therapy treatments at Novartis, Semma Therapeutics, Magenta
and Vertex,” said Chen Schor, President and Chief Executive Officer
of Adicet. “We are delighted to welcome him to Adicet’s board, and
look forward to his contributions as we continue to advance ADI-001
into the clinic and expand our pipeline of ‘off-the-shelf’ gamma
delta T cell product candidates.”
“Adicet’s gamma delta T cell platform and pipeline provide a
differentiated opportunity to enhance selective tumor targeting,
facilitate innate and adaptive anti-tumor immune response, and
improve persistence for durable activity in cancer patients,” said
Dr. Sanna. "I'm excited to be joining the Board, and look forward
to helping Adicet advance its mission of delivering potentially
efficacious next generation cell therapy treatments to patients
with solid and hematologic tumors.”
At Vertex, Dr. Sanna is responsible for advancing the research,
development and manufacturing of all of Vertex’s cell and genetic
therapy programs. Previously, Dr. Sanna was Chief Executive Officer
of Semma Therapeutics (acquired by Vertex in 2019). Under his
leadership, the Company pioneered the development of cell therapy
treatments for type 1 diabetes. Prior to that, he served as Chief
Operating Officer at Magenta Therapeutics and as the Global Program
Head of Stem Cell Transplant and early programs at Novartis, where
he oversaw clinical, regulatory, CMC and commercial aspects of
programs in bone marrow transplant and CAR-T cell therapies. Dr.
Sanna holds a Ph.D. in Biotechnology from the University of
Sassari.
About Adicet Bio, Inc.
Adicet Bio, Inc. is a biotechnology company discovering and
developing allogeneic gamma delta T cell therapies for cancer and
other diseases. Adicet is advancing a pipeline of “off-the-shelf”
gamma delta T cells, engineered with chimeric antigen receptors and
T cell receptor-like antibodies to enhance selective tumor
targeting, facilitate innate and adaptive anti-tumor immune
response, and improve persistence for durable activity in
patients. For more information, please visit our website
at http://www.adicetbio.com.
Forward-Looking StatementsThis press release
contains "forward-looking statements" of Adicet within the meaning
of the Private Securities Litigation Reform Act of 1995 relating to
business and operations of Adicet including, but not limited to,
preclinical and clinical development of Adicet’s product
candidates, including future plans or expectations for ADI-001 and
potential therapeutic effects of ADI-001. Any forward-looking
statements in this press release are based on management’s current
expectations and beliefs of future events, and are subject to a
number of risks and uncertainties that could cause actual results
to differ materially and adversely from those set forth in or
implied by such forward-looking statements, including without
limitation, the effect of COVID-19 on Adicet’s business and
financial results, including with respect to disruptions to our
clinical trials, business operations, employee hiring and
retention, and ability to raise additional capital; Adicet’s
ability to execute on its strategy; Adicet’s ability to meet
production and product release expectations; as well as those risks
and uncertainties set forth in the company’s most recent annual
report on Form 10-K and subsequent filings with the Securities
and Exchange Commission. For a discussion of these and
other risks and uncertainties, and other important factors, any of
which could cause Adicet’s actual results to differ from those
contained in the forward-looking statements, see the section
entitled “Risk Factors” in Adicet’s most recent annual report on
Form 10-K and our periodic reports on Form 10-Q and Form 8-K filed
with the SEC, as well as discussions of potential risks,
uncertainties, and other important factors in Adicet’s other
filings with the SEC. All information in this press release is
as of the date of the release, and Adicet undertakes no duty
to update this information unless required by law.
Adicet Bio., Inc.Investor and Media
ContactsAnne
Bowdidgeabowdidge@adicetbio.com
Janhavi MohiteStern Investor Relations,
Inc.212-362-1200janhavi.mohite@sternir.com
Adicet Bio (NASDAQ:ACET)
Historical Stock Chart
From Mar 2024 to Apr 2024
Adicet Bio (NASDAQ:ACET)
Historical Stock Chart
From Apr 2023 to Apr 2024